Cardiovascular Diabetology

1. Cardiovasc Diabetol21 Aug 2025

   Evaluative performance of TyG-ABSI versus traditional indices in relation to cardiovascular disease and mortality: evidence from the U.S. NHANES

   Cross-sectional study

2. Cardiovasc Diabetol20 Aug 2025

   Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis

   Cohort studyT2D & other

3. Cardiovasc Diabetol18 Aug 2025

   A decline in renal function is associated with a reduction in myocardial mechano-energetic efficiency in individuals at high cardiometabolic risk

   Cross-sectional study

4. Cardiovasc Diabetol18 Aug 2025

   Unveiling biomarkers via plasma metabolome profiling for diabetic macrovascular and microvascular complications

   Cohort studyComplications

5. Cardiovasc Diabetol18 Aug 2025

   Heme oxygenase-1 polymorphisms associate with ischemic cardiac complications and all-cause mortality in type 1 diabetes

   Research articleT1D

6. Cardiovasc Diabetol18 Aug 2025

   Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study

   Cohort studyT2D & other

7. Cardiovasc Diabetol18 Aug 2025

   Prognostic value of triglyceride-glucose index combined with stress hyperglycemia ratio for all-cause mortality in critically ill patients with stroke

   Cohort study

8. Cardiovasc Diabetol18 Aug 2025

   Predictive value and robustness of the stress hyperglycemia ratio combined with hypertension for stroke risk: evidence from the CHARLS cohort

   Cohort study

9. Cardiovasc Diabetol14 Aug 2025

   Association of circulating metabolites and polygenic risk score with incident type 2 diabetes: a prospective community-based cohort study

   Cohort studyT2D & other

10. Cardiovasc Diabetol13 Aug 2025

    Cardiovascular autonomic neuropathy defined by indices of heart rate variability is associated with cardiovascular disease: a longitudinal cohort study of participants with type 1 diabetes

    Cohort studyComplications

11. Cardiovasc Diabetol13 Aug 2025

    The predictive value of atherogenic index of plasma and clonal hematopoiesis of indeterminate potential among patients with STEMI—from a prospective cohort study

    Cohort study

12. Cardiovasc Diabetol12 Aug 2025

    Association of triglyceride-glucose-related indices with all-cause and cause-specific mortality in individuals with prediabetesss

    Cohort studyT2D & other

13. Cardiovasc Diabetol12 Aug 2025

    The novel triglyceride‒glucose-weighted adjusted waist index as a supplementary diagnostic tool for heart failure: evidence of improved reclassification beyond traditional TyG-related indices from a cross-sectional study

    Cross-sectional study

14. Cardiovasc Diabetol11 Aug 2025

    Global detection and management of dysglycaemic patients with coronary artery disease results from the INTERASPIRE survey from 14 countries across six WHO regions

    Cross-sectional studyT2D & other

15. Cardiovasc Diabetol11 Aug 2025

    Improving cardiovascular risk stratification: the role of abdominal obesity in predicting MACEs

    Cohort studyObesity

16. Cardiovasc Diabetol10 Aug 2025

    Development and validation of a machine learning model for predicting vulnerable carotid plaques using routine blood biomarkers and derived indicators: insights into sex-related risk patterns

    Cohort study

17. Cardiovasc Diabetol9 Aug 2025

    Epicardial adipose tissue volume is associated with impaired left ventricular strain in patients with metabolic syndrome: the mediating role of myocardial energetic efficiency

    Cross-sectional study

18. Cardiovasc Diabetol8 Aug 2025

    Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS

    Cross-sectional studyObesity

19. Cardiovasc Diabetol7 Aug 2025

    Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls

    Case-control studyT1D

20. Cardiovasc Diabetol6 Aug 2025

    Glucose metabolism in heterozygous familial hypercholesterolemia with a founder effect and a high diabetes prevalence: a cross-sectional study

    Cross-sectional studyT2D & other

21. Cardiovasc Diabetol6 Aug 2025

    Longitudinal study reveals plasma glycans associations with prediabetes/type 2 diabetes in KORA study

    Cohort studyT2D & other

22. Cardiovasc Diabetol6 Aug 2025

    Biological aging and incident cardiovascular diseases in individuals with diabetes: insights from a large prospective cohort study

    Cohort studyT2D & other

23. Cardiovasc Diabetol4 Aug 2025

    Does diabetes status modify the association between the triglyceride-glucose index and major adverse cardiovascular events in patients with coronary heart disease? A systematic review and meta-analysis of longitudinal cohort studies

    Meta-analysisT2D & other

24. Cardiovasc Diabetol4 Aug 2025

    Predictive value of the combined triglyceride-glucose and frailty index for cardiovascular disease and stroke in two prospective cohorts

    Cohort study

25. Cardiovasc Diabetol1 Aug 2025

    Association between the C-reactive protein-triglyceride glucose index and new-onset coronary heart disease among metabolically heterogeneous individuals

    Cross-sectional studyObesity

26. Cardiovasc Diabetol1 Aug 2025

    Metabolomic profiling reveals interindividual metabolic variability and its association with cardiovascular-kidney-metabolic syndrome risk

    Cross-sectional study

27. Cardiovasc Diabetol1 Aug 2025

    Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study

    Cohort studyT2D & other

28. Cardiovasc Diabetol1 Aug 2025

    Blood plasma proteome-wide association study implicates novel proteins in the pathogenesis of multiple cardiovascular diseases

    Cohort study

29. Cardiovasc Diabetol1 Aug 2025

    Association of C-reactive protein-triglyceride glucose index with the incidence and mortality of cardiovascular disease: a retrospective cohort study

    Cohort study

30. Cardiovasc Diabetol30 Jul 2025

    Glucokinase activator, circulating metabolites, and cardio-cerebrovascular diseases: a Mendelian randomization study

    Research article

31. Cardiovasc Diabetol30 Jul 2025

    Microvascular dysfunction across organs in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study

    Case-control study

32. Cardiovasc Diabetol30 Jul 2025

    Triglyceride glucose-weight-adjusted waist index as a cardiovascular mortality predictor: incremental value beyond the establishment of TyG-related indices

    Cohort study

33. Cardiovasc Diabetol30 Jul 2025

    Diabetic kidney disease phenotypes and the risk of cardiovascular events: The Silesia Diabetes-Heart Project

    Cohort studyComplications

34. Cardiovasc Diabetol30 Jul 2025

    Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

    Secondary analysisT2D & other

35. Cardiovasc Diabetol26 Jul 2025

    Triglyceride-glucose index: a novel assessment tool for all-cause mortality in critical stroke patients—a retrospective analysis of the eICU-CRD database

    Cohort study

36. Cardiovasc Diabetol26 Jul 2025

    Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident cardiovascular disease in middle-aged and older Chinese adults: a nationwide cohort study

    Cohort study

37. Cardiovasc Diabetol24 Jul 2025

    Association of novel triglyceride-glucose-related indices with incident stroke in early-stage cardiovascular-kidney-metabolic syndrome

    Cohort study

38. Cardiovasc Diabetol24 Jul 2025

    Trace elements and risk of diabetes-related vascular complications: results from the EPIC-Potsdam cohort study

    Cohort studyComplications

39. Cardiovasc Diabetol24 Jul 2025

    Association between triglyceride-glucose-body mass index and adverse prognosis in elderly patients with severe heart failure and type 2 diabetes: a retrospective study based on the MIMIC-IV database

    Cohort studyT2D & other

40. Cardiovasc Diabetol24 Jul 2025

    Prognostic impact of type 2 diabetes mellitus and coronary microvascular dysfunction in patients undergoing rotational atherectomy during PCI

    Cohort studyT2D & other

All 1,291 Briefs in ExploreShowing Briefs 361–400 of 1,291, newest first